$2.65 Million in Sales Expected for Albireo Pharma, Inc. (NASDAQ:ALBO) This Quarter


Share on StockTwits

Equities analysts expect Albireo Pharma, Inc. (NASDAQ:ALBO) to report $2.65 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Albireo Pharma’s earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Albireo Pharma reported sales of $1.55 million during the same quarter last year, which would suggest a positive year over year growth rate of 71%. The company is expected to report its next earnings report before the market opens on Thursday, May 6th.

According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $14.05 million for the current year, with estimates ranging from $2.11 million to $19.50 million. For the next fiscal year, analysts forecast that the business will report sales of $76.46 million, with estimates ranging from $23.48 million to $151.46 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last announced its earnings results on Wednesday, February 24th. The biopharmaceutical company reported ($1.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.90) by $0.60. Albireo Pharma had a negative net margin of 751.53% and a negative return on equity of 71.22%. The company had revenue of $2.72 million during the quarter, compared to the consensus estimate of $2.23 million.

A number of equities research analysts have recently commented on ALBO shares. Zacks Investment Research upgraded Albireo Pharma from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 17th. Piper Sandler increased their target price on shares of Albireo Pharma from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Monday, March 8th. Robert W. Baird reaffirmed a “buy” rating and issued a $67.00 price target on shares of Albireo Pharma in a report on Monday, March 1st. Finally, Jefferies Financial Group increased their price objective on Albireo Pharma from $79.00 to $82.00 and gave the company a “buy” rating in a report on Friday, March 26th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Albireo Pharma has an average rating of “Buy” and an average target price of $66.50.

Shares of Albireo Pharma stock opened at $30.37 on Wednesday. The business’s fifty day simple moving average is $33.61 and its 200 day simple moving average is $36.06. The company has a current ratio of 13.52, a quick ratio of 13.51 and a debt-to-equity ratio of 0.04. Albireo Pharma has a 12 month low of $22.08 and a 12 month high of $49.00. The firm has a market capitalization of $582.92 million, a P/E ratio of -4.95 and a beta of 1.62.

In related news, insider Jan Mattsson sold 31,470 shares of the business’s stock in a transaction dated Wednesday, March 3rd. The stock was sold at an average price of $36.85, for a total transaction of $1,159,669.50. Insiders sold 32,374 shares of company stock worth $1,190,686 over the last three months. 5.00% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of ALBO. Pacer Advisors Inc. purchased a new stake in Albireo Pharma in the fourth quarter worth $40,000. Chicago Capital LLC increased its position in shares of Albireo Pharma by 21.1% during the fourth quarter. Chicago Capital LLC now owns 618,263 shares of the biopharmaceutical company’s stock valued at $23,191,000 after buying an additional 107,820 shares during the period. State of Wisconsin Investment Board lifted its holdings in Albireo Pharma by 19.2% in the fourth quarter. State of Wisconsin Investment Board now owns 31,600 shares of the biopharmaceutical company’s stock worth $1,185,000 after buying an additional 5,100 shares during the period. Los Angeles Capital Management LLC boosted its position in Albireo Pharma by 87.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 39,165 shares of the biopharmaceutical company’s stock valued at $1,469,000 after acquiring an additional 18,275 shares in the last quarter. Finally, Swiss National Bank purchased a new position in shares of Albireo Pharma during the 4th quarter worth approximately $1,287,000. 85.65% of the stock is currently owned by hedge funds and other institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Balance Sheet

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.